Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix Announces Collaboration with Centre for Proteomic and Genomic Research (CPGR)

Published: Tuesday, November 20, 2012
Last Updated: Tuesday, November 20, 2012
Bookmark and Share
CPGR will provide gene expression and Axiom genotyping services to African researchers using GeneTitan® Multi-Channel (MC) Instrument.

The Affymetrix and CPGR partnership aims to enable high-throughput genomics research and personalized medicine projects across Africa.

The CPGR is a nonprofit organization funded by the Technology Innovation Agency (TIA), which is based on an initiative by the Department of Science and Technology (DST) whose goal is to develop the bio-economy in South Africa. According to Dr Reinhard Hiller, Managing Director of the CPGR, “The high throughput capability of GeneTitan® MC Instrument combined with customizable Axiom® Genotyping Arrays is ideal for meeting the needs of scientists in Africa whose research projects range from small pilot to large-scale discovery to focused validation studies. GeneTitan® MC Instrument expands our genomics service capabilities and will further enable CPGR to support cutting-edge translational research in Africa. Further, it allows discovery and validation of disease-related biomarkers economically – even when searching for very rare genetic variants. We expect to progress personalized medicine studies that aim to discover genetic markers specific in the African population for better diagnosis and drug treatment.”

It is a well-known fact that genetic variability of African populations is far greater than in other regions in the world. This is particularly important when considering that African populations are underrepresented in most studies on hereditary diseases and pharmacogenomics. Applying these types of genomic discoveries to clinical practices has the potential to change health and wellness of African populations.

“We are excited to partner with CPGR and see this as a significant opportunity to ensure that African populations are represented in genomics research studies leading to personalized therapies. Affymetrix is leading the way in population optimized genotyping analysis and was the first to create a genotyping array with content derived specifically from African populations,” said Chris Barbazette, VP of Commercial Operations, International Markets at Affymetrix.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Affymetrix, BioRealm, RUCDR Ally
Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.
Wednesday, July 08, 2015
Affymetrix Acquires Assets of Eureka Genomics
Aquisition will enable provision of high throughput and economical crop and animal genotyping.
Thursday, May 14, 2015
CollabRx, Affymetrix To Develop Analytical Tools For Integrated Clinical Cancer Panels
The overall objective of the partnership is to provide scientific knowledge for biomarker CNV profiles in cancer.
Wednesday, April 16, 2014
Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data
Generated from FFPE solid tumor samples for accelerating cancer translational research.
Thursday, April 11, 2013
Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership
Agreement for diagnostic test development for pathogen detection.
Monday, August 27, 2012
Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019
Company expects to grant an option to purchase up to $10 million aggregate principal amount of additional notes.
Thursday, June 21, 2012
Affymetrix Announces Research Collaboration with MGH
Collaboration and licensing agreement to validate and develop new oncology biomarker tests.
Thursday, June 07, 2012
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement for CTC Technology
Combination of ScreenCell’s isolation devices and Affymetrix’ QuantiGene® ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.
Friday, May 18, 2012
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement
Affymetrix releases first circulating tumour cell platform technology for 4-color RNA-ISH.
Friday, May 18, 2012
Affymetrix and BGI Enter Strategic Collaboration
Partnership to co-develop and commercialize genomic microarrays for the agricultural community.
Friday, January 13, 2012
Affymetrix to Acquire eBioscience
Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments. The transaction is subject to customary closing conditions.
Wednesday, December 14, 2011
Affymetrix Releases Axiom Genome-Wide Pan-African Array
The highest genomic coverage of African and African American genomes for disease association studies.
Friday, October 21, 2011
Affymetrix Releases Data from Validated SNP Database for Design of Custom Genotyping Arrays
Validated SNPs from 1000 genomes project and custom Axiom arrays will enable the next wave of genotyping studies.
Tuesday, July 27, 2010
Affymetrix Delivers First Custom Axiom Array for Kaiser Permanente/UCSF Genotyping Project
6,000-sample pilot studies completed on Axiom catalog array with superior performance.
Tuesday, May 11, 2010
Developing Countries Sign up for Pharmacogenomics for Every Nation Initiative Using the Affymetrix DMET™ Plus Panel
IPIT at the University of North Carolina in Chapel Hill is using the company’s DMET™ Plus biomarker panel to expand PGENI.
Wednesday, October 28, 2009
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!